title: Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography.
abstract: OBJECTIVE
  Previous proteomics experiments have demonstrated that several proteins are differentially expressed in vulnerable human carotid plaques compared with stable plaques. This study aims to investigate the prognostic value of 13 such circulating biomarkers in patients with coronary artery disease.
  
  
  RESULTS
  Between 2008 and 2011, 768 patients who underwent coronary angiography for acute coronary syndrome or stable angina pectoris were included in a prospective biomarker study. Plasma concentrations of 13 biomarkers were measured in 88 patients who experienced a major adverse cardiovascular event (MACE) within 1 year and 176 control patients without MACE who were matched on age, sex, and number of diseased coronary vessels. MACE comprised all-cause mortality, acute coronary syndrome, unplanned coronary revascularization, and stroke. After adjustment for established cardiovascular risk factors, osteoglycin (OGN; odds ratio per SD increase in ln-transformed OGN, 1.53; 95% confidence interval, 1.11-2.11; P=0.010) and neutrophil gelatinase-associated lipocalin/matrix metalloproteinase 9 (NGAL/MMP9; odds ratio per SD increase in ln-transformed NGAL/MMP9, 1.37; 95% confidence interval, 1.01-1.85; P=0.042) complex were independently associated with MACE during follow-up. These associations were independent of C-reactive protein levels. Adding OGN or NGAL/MMP9 to a model containing conventional risk factors did not significantly improve discriminatory power (OGN: area under receiver operating characteristic curve, 0.75 versus 0.67; NGAL/MMP9: 0.73 versus 0.67) but did significantly improve risk reclassification (OGN: net reclassification index=0.29; 95% confidence interval, 0.05-0.53; P<0.019; NGAL/MMP9: net reclassification index=0.44; 95% confidence interval, 0.20-0.69; P<0.001).
  
  
  CONCLUSIONS
  Circulating OGN and NGAL/MMP9 complex are promising biomarkers that are expressed in vulnerable atherosclerotic plaques and may have incremental value for prediction of MACE within 1 year after coronary angiography.
authors.affiliation: From the Erasmus MC, Department of Cardiology, Rotterdam, The Netherlands (J.M.C., K.M.A., R.M.O., H.M.G.-G., R.-J.v.G., P.W.S., E.B., I.K.); INSERM U698, Bichat Hospital, Paris, France (O.M.); CHU de La Reunion, Saint-Denis, La Reunion, France (O.M.); UMR3145 CNRS Bio-Rad, Sysdiag Laboratory, Montpellier, France (D.P., D.M., E.d.P., P.G., J.F.); INSERM, Université Pierre et Marie Curie, Centre de Recherche des Cordeliers, Paris, France (F.J.); INSERM, Centre d'Investigations Cliniques 9501 and INSERM U1116, Nancy, France (P.R.); CHU Nancy, Institut Lorrain du Cœur et des Vaisseaux, Vandoeuvre lès Nancy, France (P.R.); and Université de Lorraine, Lorraine, France (P.R.).
authors.forename: Jin M
authors.initials: JM
authors.lastname: Cheng
authors.forename: K Martijn
authors.initials: KM
authors.lastname: Akkerhuis
authors.forename: Olivier
authors.initials: O
authors.lastname: Meilhac
authors.forename: Rohit M
authors.initials: RM
authors.lastname: Oemrawsingh
authors.forename: Hector M
authors.initials: HM
authors.lastname: Garcia-Garcia
authors.forename: Robert-Jan
authors.initials: RJ
authors.lastname: van Geuns
authors.forename: Dominique
authors.initials: D
authors.lastname: Piquer
authors.forename: Delphine
authors.initials: D
authors.lastname: Merle
authors.forename: Emilie
authors.initials: E
authors.lastname: du Paty
authors.forename: Pascale
authors.initials: P
authors.lastname: Galéa
authors.forename: Frederic
authors.initials: F
authors.lastname: Jaisser
authors.forename: Patrick
authors.initials: P
authors.lastname: Rossignol
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
authors.forename: Eric
authors.initials: E
authors.lastname: Boersma
authors.forename: Jeannette
authors.initials: J
authors.lastname: Fareh
authors.forename: Isabella
authors.initials: I
authors.lastname: Kardys
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000000981:diagnostic imaging; D000209:Acute-Phase Proteins; D000368:Aged; D019540:Area Under Curve; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood* / Q000000981:diagnostic imaging* / Q000401:mortality / Q000628:therapy; D016002:Discriminant Analysis; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood*; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D009204:Myocardial Revascularization; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D011518:Proto-Oncogene Proteins / Q000097:blood*; D012372:ROC Curve; D012307:Risk Factors; D020521:Stroke / Q000097:blood / Q000000981:diagnostic imaging; D013997:Time Factors
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; D036341:Intercellular Signaling Peptides and Proteins; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; C063488:OGN protein, human; D011518:Proto-Oncogene Proteins; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9
keywords: OGN protein, human; atherosclerosis; biological markers; prognosis